The use of tirzepatide to successfully treat persistent genital arousal disorder/genitopelvic dysesthesia: a case report.

IF 2 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Sexual Medicine Pub Date : 2025-09-24 eCollection Date: 2025-08-01 DOI:10.1093/sexmed/qfaf073

Eliza Burr, Maya Roytman, Évéline Poirier, Marta Kolbuszewska, James G Pfaus, Barry R Komisaruk, Irwin Goldstein, Rachel Rubin

{"title":"The use of tirzepatide to successfully treat persistent genital arousal disorder/genitopelvic dysesthesia: a case report.","authors":"Eliza Burr, Maya Roytman, Évéline Poirier, Marta Kolbuszewska, James G Pfaus, Barry R Komisaruk, Irwin Goldstein, Rachel Rubin","doi":"10.1093/sexmed/qfaf073","DOIUrl":null,"url":null,"abstract":"Introduction: Persistent genital arousal disorder/genitopelvic dysesthesia (PGAD/GPD) is associated with poor quality of life. Due to social stigma and its heterogeneous nature, many patients suffer without treatment.Aims: This case presents the first example of the successful use of a glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist (GLP1/GIP RA) medication for the treatment of PGAD/GPD.Methods: The patient was identified by the Sexual Medicine Research Team, retained as a patient at a sexual medicine clinic, and interviewed for the purposes of this case report.Results: This case presents a 44-year-old woman with a lifelong history of PGAD/GPD symptoms that caused extreme distress and depression who experienced 95% resolution of her symptoms within 2 days of starting tirzepatide, a GLP1/GIPRA medication, for weight loss.Conclusion: Increasing benefits of GLP1/GIPRAs are being uncovered, and further studies must investigate the potential for these medications to be used in patients with PGAD/GPD. This study also provides a potential mechanism for decreased arousal resulting from GLP1/GIP receptor activation in attention/reward pathways in the brain.","PeriodicalId":21782,"journal":{"name":"Sexual Medicine","volume":"13 4","pages":"qfaf073"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12459093/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sexual Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/sexmed/qfaf073","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Persistent genital arousal disorder/genitopelvic dysesthesia (PGAD/GPD) is associated with poor quality of life. Due to social stigma and its heterogeneous nature, many patients suffer without treatment.

Aims: This case presents the first example of the successful use of a glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist (GLP1/GIP RA) medication for the treatment of PGAD/GPD.

Methods: The patient was identified by the Sexual Medicine Research Team, retained as a patient at a sexual medicine clinic, and interviewed for the purposes of this case report.

Results: This case presents a 44-year-old woman with a lifelong history of PGAD/GPD symptoms that caused extreme distress and depression who experienced 95% resolution of her symptoms within 2 days of starting tirzepatide, a GLP1/GIPRA medication, for weight loss.

Conclusion: Increasing benefits of GLP1/GIPRAs are being uncovered, and further studies must investigate the potential for these medications to be used in patients with PGAD/GPD. This study also provides a potential mechanism for decreased arousal resulting from GLP1/GIP receptor activation in attention/reward pathways in the brain.

查看原文本刊更多论文

使用替西帕肽成功治疗持续性生殖器觉醒障碍/生殖盆腔感觉不良：一例报告。

导语：持续性生殖器觉醒障碍/生殖盆腔感觉障碍（PGAD/GPD）与生活质量差有关。由于社会污名及其异质性，许多患者没有得到治疗。目的：本病例是第一个成功使用胰高血糖素样肽1和葡萄糖依赖性胰岛素性多肽受体激动剂（GLP1/GIP RA）药物治疗PGAD/GPD的例子。方法：患者由性医学研究小组确定，作为性医学诊所的患者保留，并为本病例报告的目的进行访谈。结果：该病例是一名44岁的女性，她一生都有pad /GPD症状史，导致极度痛苦和抑郁，在开始使用替西帕肽（一种GLP1/GIPRA药物）减肥后的2天内，她的症状缓解了95%。结论：GLP1/GIPRAs的益处正在被发现，进一步的研究必须调查这些药物在PGAD/GPD患者中的应用潜力。该研究还提供了大脑中注意/奖励通路中GLP1/GIP受体激活导致觉醒减少的潜在机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Sexual Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

5.40

自引率

0.00%

发文量

103

审稿时长

22 weeks

期刊介绍： Sexual Medicine is an official publication of the International Society for Sexual Medicine, and serves the field as the peer-reviewed, open access journal for rapid dissemination of multidisciplinary clinical and basic research in all areas of global sexual medicine, and particularly acts as a venue for topics of regional or sub-specialty interest. The journal is focused on issues in clinical medicine and epidemiology but also publishes basic science papers with particular relevance to specific populations. Sexual Medicine offers clinicians and researchers a rapid route to publication and the opportunity to publish in a broadly distributed and highly visible global forum. The journal publishes high quality articles from all over the world and actively seeks submissions from countries with expanding sexual medicine communities. Sexual Medicine relies on the same expert panel of editors and reviewers as The Journal of Sexual Medicine and Sexual Medicine Reviews.